肝脏炎症与纤维化是与活检确诊MASLD中期死亡率相关的特征:日本多中心研究
本研究纳入1349例活检确诊的代谢功能障碍相关脂肪性肝病(MASLD)患者,观察8010人年,采用Cox回归和数据分析探讨与中期死亡率相关的病理特征。45例死亡,肝相关事件最常见(40%)。2/3级小叶炎症和3/4期纤维化分别与1.9倍和1.8倍死亡风险相关。
要点
- 活检确诊MASLD患者中MASH患病率65.6%,3/4期纤维化占17.4%。
- 45例死亡中肝相关事件占40%(n=18),肝外恶性肿瘤占26.7%(n=12)。
- 2/3级小叶炎症和3/4期纤维化分别与1.9倍和1.8倍死亡风险相关。
核心结论
- 在活检确诊的MASLD患者中,MASH和进展期纤维化的患病率分别约为65%和20%。
- 死亡的最主要原因是肝相关事件。
- 肝脏炎症和纤维化是影响中期死亡率的重要因素。
- 这些发现凸显了在MASLD管理中针对炎症和纤维化的重要性。
研究设计与样本
- 日本多中心研究,纳入1349例活检确诊的MASLD患者,观察期为8010人年。
- 采用Cox回归分析评估与死亡率相关的独立因素,并使用数据挖掘分析探讨与死亡率相关的病理特征。
主要发现
- MASH患病率为65.6%,3/4期纤维化患病率为17.4%。
- 45例MASLD患者死亡,其中肝相关事件最常见,占40%(n=18),其次为肝外恶性肿瘤,占26.7%(n=12)。
- 2/3级小叶炎症和3/4期纤维化的死亡风险分别为1.9倍和1.8倍。
- 决策树分析显示,预后最差的特征为2/3级肝脏炎症伴进展期气球样变(1/2级)和纤维化(3/4期),该特征死亡率为8.3%。
- 随机森林分析确定肝脏纤维化和炎症是影响MASLD患者中期预后的第一和第二位因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: A multi-stakeholder consensus has proposed MASLD (metabolic dysfunction-associated steatotic liver disease). We aimed to investigate the pathological findings related to the mid-term mortality of patients with biopsy-proven MASLD in Japan. METHODS: We enrolled 1349 patients with biopsy-proven MASLD. The observational period was 8010 person years. We evaluated independent factors associated with mortality in patients with MASLD by Cox regression analysis. We also investigated pathological profiles related to mortality in patients with MASLD using data-mining analysis. RESULTS: The prevalence of MASH and stage 3/4 fibrosis was observed in 65.6% and 17.4%, respectively. Forty-five patients with MASLD died. Of these, liver-related events were the most common cause at 40% (n = 18), followed by extrahepatic malignancies at 26.7% (n = 12). Grade 2/3 lobular inflammation and stage 3/4 fibrosis had a 1.9-fold and 1.8-fold risk of mortality, respectively. In the decision-tree analysis, the profiles with the worst prognosis were characterised by Grade 2/3 hepatic inflammation, along with advanced ballooning (grade 1/2) and fibrosis (stage 3/4). This profile showed a mortality at 8.3%. Furthermore, the random forest analysis identified that hepatic fibrosis and inflammation were the first and second responsible factors for the mid-term prognosis of patients with MASLD. CONCLUSIONS: In patients with biopsy-proven MASLD, the prevalence of MASH and advanced fibrosis was approximately 65% and 20%, respectively. The leading cause of mortality was liver-related events. Hepatic inflammation and fibrosis were significant factors influencing mid-term mortality. These findings highlight the importance of targeting inflammation and fibrosis in the management of patients with MASLD.
引用
- Tsutsumi T, Kawaguchi T, Fujii H, et al. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan. Aliment Pharmacol Ther. 2024. PMID: 38651312. doi:10.1111/apt.17995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。